P21 vs Semax
P21 (Neurogenic research peptide (Cerebrolysin/CNTF-related)) and Semax (Synthetic ACTH(4-10) analog (heptapeptide)) are documented as co-studied in the PeptiDex library. This page puts the two entries side by side on class, molecular weight, half-life, origin, mechanism and studied research areas — every value taken from the entry it belongs to.
Why these two are co-studied
Cross-referenced for research context — not a usage or combination recommendation.
At a glance
| Attribute | P21 | Semax |
|---|---|---|
| Compound class | Neurogenic research peptide (Cerebrolysin/CNTF-related) | Synthetic ACTH(4-10) analog (heptapeptide) |
| Research category | Cognitive & Nootropic | Cognitive & Nootropic |
| Length (amino acids) | Not documented | 7 amino acids |
| Molecular weight | Not documented | 813.9 g/mol |
| Half-life | Not documented | ~2-5 minutes (plasma) |
| Origin | P21 (also referred to as P021 in the literature) is a small peptidergic compound derived from a biologically active region of ciliary neurotrophic factor (CNTF), developed in academic neuroscience research as a neurogenic candidate. | Semax was developed in Russia (Institute of Molecular Genetics, Russian Academy of Sciences) as a synthetic analog of a fragment of adrenocorticotropic hormone (ACTH 4-10) with an added Pro-Gly-Pro tail for stability. It is marketed in Russia and some neighboring countries. |
“Not documented” means the PeptiDex entry records no value for that field. Nothing on this page is estimated, and no figure is carried over from one compound to the other.
How P21 works
P021 is described as an adamantylated, blood-brain-barrier-permeable derivative of a CNTF peptide fragment. Preclinical research reports it can enhance neurogenesis and neurotrophic signaling, including effects on BDNF, and has been studied for reduction of abnormal tau hyperphosphorylation in models of neurodegeneration. Its detailed human pharmacology is not established.
How Semax works
Semax is an analog of the ACTH(4-10) melanocortin fragment but is described as being devoid of hormonal (corticotropic) activity. Research reports that it influences brain-derived neurotrophic factor (BDNF) and its receptor TrkB, modulates the expression of neurotrophin-related and immune genes, and may affect monoaminergic systems. It has been studied for neuroprotective and nootropic effects, potentially via effects on the melanocortin system.
Mechanistic descriptions reflect published research-literature understanding and are quoted from each compound's own entry. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
Where each one appears in the literature
The research contexts each entry documents. Listing a research area is not a claim of efficacy or a therapeutic indication, and the two lists are not scored against each other.
P21
Semax
What sets each apart
P21
P21/P021 is distinguished by its CNTF-derived, neurogenesis-focused mechanism, differing from HGF-modulating (Dihexa) or melanocortin (Semax) peptides.
Semax
Semax is a melanocortin (ACTH)-derived peptide oriented toward neuroprotection and cognition, whereas Selank derives from tuftsin and is oriented toward anxiolysis.
Frequently asked questions
How does P21 relate to Adamax?
P21 and Adamax are sometimes conflated in vendor materials, but they are distinct compounds: P21 is a CNTF-derived neurotrophic mimetic, while Adamax is an adamantane-modified analog in the Semax/ACTH family. Both are studied around BDNF-linked mechanisms, which contributes to the confusion.
What is P21 (P021)?
P21, also written P021, is a synthetic peptidomimetic derived from an active region of ciliary neurotrophic factor (CNTF), with an adamantylated glycine added to improve stability and lipophilicity. It is studied in preclinical models of neurogenesis, synaptic plasticity, and neurodegeneration.
What is P21's proposed mechanism?
In preclinical reports P21 is proposed to enhance BDNF expression and downstream TrkB/CREB signaling while avoiding the leukemia-inhibitory-factor-associated side effects of the parent molecule CNTF. This is put forward as the basis for its reported neurogenic and neurotrophic effects.
What is Semax and what is it studied for?
Semax is a synthetic heptapeptide that adds a stabilizing Pro-Gly-Pro tail to the ACTH(4-7) fragment, developed at the Russian Academy of Sciences. It is studied in research models of cognition, attention, memory, and neuroprotection, where it is reported to upregulate BDNF and NGF messenger RNA in the hippocampus and cortex.
How does Semax achieve long effects despite a very short half-life?
The parent peptide has a plasma half-life of only about 2-5 minutes, yet its transcriptional effects on neurotrophic factors are measured over hours. The Pro-Gly-Pro tail slows peptidase cleavage relative to the native ACTH(4-7) fragment, allowing enough exposure to drive downstream BDNF/NGF signaling that outlasts the peptide itself.
Why is intranasal delivery emphasized in Semax research?
Intranasal administration provides direct nose-to-brain transport, achieving rapid CNS exposure without depending on blood-brain-barrier crossing from systemic circulation. Given the peptide's very short plasma half-life, this route is a common design choice in cognition and neuroprotection studies.
Answers are the ones published on each compound's own PeptiDex entry. They are educational summaries of research-literature context and are not medical advice.